Risk factors for treatment failure in women with uncomplicated lower urinary tract infection.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 30 04 2021
accepted: 06 08 2021
entrez: 31 8 2021
pubmed: 1 9 2021
medline: 15 12 2021
Statut: epublish

Résumé

Given rising antibiotic resistance and increasing use of delayed prescription for uncomplicated lower urinary tract infections (UTI), patients at risk for treatment failure should be identified early. We assessed risk factors for clinical and microbiological failure in women with lower UTI. This case-control study nested within a randomized clinical trial included all women in the per-protocol population (PPP), those in the PPP with microbiologically confirmed UTI, and those in the PPP with UTI due to Escherichia coli. Cases were women who experienced clinical and/or microbiologic failure; controls were those who did not. Risk factors for failure were assessed using multivariate logistic regression. In the PPP, there were 152 clinical cases for 307 controls. Among 340 women with microbiologically confirmed UTI, 126 and 102 cases with clinical and microbiological failure were considered with, respectively, 214 and 220 controls. Age ≥52 years was independently associated with clinical (adjusted OR 3.01; 95%CI 1.84-4.98) and microbiologic failure (aOR 2.55; 95%CI 1.54-4.25); treatment with fosfomycin was associated with clinical failure (aOR 2.35; 95%CI 1.47-3.80). The association with age persisted among all women, and women with E. coli-related UTI. Diabetes was not an independent risk factor, nor were other comorbidities. Postmenopausal age emerged as an independent risk factor for both clinical and microbiological treatment failure in women with lower UTI and should be considered to define women at-risk for non-spontaneous remission, and thus for delayed antibiotic therapy; diabetes mellitus was not associated with failure.

Identifiants

pubmed: 34464397
doi: 10.1371/journal.pone.0256464
pii: PONE-D-21-14320
pmc: PMC8407559
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0256464

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Diabetes Care. 2002 Oct;25(10):1778-83
pubmed: 12351477
J Infect. 2018 Feb;76(2):121-131
pubmed: 29128389
BMC Infect Dis. 2015 Feb 27;15:105
pubmed: 25880328
Clin Infect Dis. 2000 Dec;31(6):1380-5
pubmed: 11096006
BMC Fam Pract. 2013 May 31;14:71
pubmed: 23721260
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404856
J Antimicrob Chemother. 2011 Apr;66(4):928-35
pubmed: 21393172
Arch Gerontol Geriatr. 2012 Jul-Aug;55(1):145-7
pubmed: 21963175
J Antimicrob Chemother. 2001 Dec;48(6):895-901
pubmed: 11733475
Clin Geriatr Med. 2016 Aug;32(3):523-38
pubmed: 27394021
Lancet. 2008 Mar 1;371(9614):760-70
pubmed: 18313505
Lancet Infect Dis. 2002 Nov;2(11):659-66
pubmed: 12409046
Eur J Clin Microbiol Infect Dis. 2015 Jun;34(6):1119-24
pubmed: 25655756
Eur J Clin Microbiol Infect Dis. 2019 Nov;38(11):2151-2158
pubmed: 31440915
BMJ. 2017 Nov 7;359:j4784
pubmed: 29113968
J Family Med Prim Care. 2019 Feb;8(2):539-543
pubmed: 30984669
BMJ. 2019 Feb 27;364:l525
pubmed: 30814048
Br J Clin Pharmacol. 2004 Aug;58(2):184-9
pubmed: 15255801
Am J Emerg Med. 2018 Jan;36(1):12-17
pubmed: 28655424
Ann Transl Med. 2017 Nov;5(21):436
pubmed: 29201888
Clin Infect Dis. 2011 Mar 1;52(5):e103-20
pubmed: 21292654
J Antimicrob Chemother. 2018 Nov 1;73(11):2916-2926
pubmed: 30184207
BMJ. 2015 Dec 23;351:h6544
pubmed: 26698878
BMJ. 2010 Feb 05;340:b5633
pubmed: 20139213
JAMA. 2018 May 1;319(17):1781-1789
pubmed: 29710295
Clin Geriatr Med. 2007 May;23(2):441-56, viii
pubmed: 17462528
J Antimicrob Chemother. 2016 Sep;71(9):2563-8
pubmed: 27246234
Antimicrob Agents Chemother. 2003 Mar;47(3):897-900
pubmed: 12604518
BMJ. 2010 May 18;340:c2096
pubmed: 20483949
Diabetes Care. 2011 Jan;34(1):230-5
pubmed: 20937688
N Engl J Med. 2013 Nov 14;369(20):1883-91
pubmed: 24224622
BMC Fam Pract. 2019 Mar 26;20(1):45
pubmed: 30914044

Auteurs

Romain Martischang (R)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.

Maciek Godycki-Ćwirko (M)

Centre for Family and Community Medicine, Faculty of Health Sciences, The Medical University of Lodz, Lodz, Poland.

Anna Kowalczyk (A)

Centre for Family and Community Medicine, Faculty of Health Sciences, The Medical University of Lodz, Lodz, Poland.

Katarzyna Kosiek (K)

Family Doctors' Clinic Pomorska96, Lodz, Poland.

Adi Turjeman (A)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Internal Medicine E, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel.

Tanya Babich (T)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Internal Medicine E, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel.

Shachaf Shiber (S)

Department of Emergency Medicine, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel.

Leonard Leibovici (L)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Internal Medicine E, Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel.

Elodie von Dach (E)

Division of Infectious Diseases, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.
Center for Clinical Research, University Hospitals of Geneva, Geneva, Switzerland.

Stephan Harbarth (S)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.
Division of Infectious Diseases, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.

Angela Huttner (A)

Infection Control Program and WHO Collaborating Centre on Patient Safety, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.
Division of Infectious Diseases, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH